Neurogene Inc.

NGNE Healthcare Biotechnology

Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00. In the quarter to June 2026, EPS fell 45.7%, free cash flow fell 23.0% and total debt fell 66.7%, each against the same quarter a year earlier.

23.27 0.68 −2.84%
Market cap
$479.3M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
n/a
Altman Z
8.68
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
10.64 13.08 16.56 18.39
Net Debt/EBITDA
6.23 7.40 9.87 11.13
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.07) (1.18) (0.82) (0.93)
Book value per Share
9.63 10.66 12.42 12.54
Free Cash Flow
(24.11) (26.40) (17.56) (19.63)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates